FDA Approves Simlandi, Biosimilar to Humira

By SPC Staff

The FDA approved adalimumab-ryvk (Simlandi, Alvotech and Teva Pharmaceuticals) injection, the first interchangeable high-concentration, citrate-free biosimilar to adalimumab (Humira, AbbVie).

According to the FDA, an interchangeable biosimilar may be substituted at the pharmacy for the reference product without the intervention of the prescribing healthcare provider, much like how generic drugs are routinely substituted for brand-name drugs.

Adalimumab-ryvk was approved to treat adult